Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):2048–2050. doi: 10.1128/aac.39.9.2048

Once-daily versus twice-daily administration of ceftazidime in the preterm infant.

J N van den Anker 1, R C Schoemaker 1, B J van der Heijden 1, H M Broerse 1, H J Neijens 1, R de Groot 1
PMCID: PMC162879  PMID: 8540714

Abstract

Ceftazidime pharmacokinetics in 28 preterm infants (gestational ages, 25.6 to 31.9 weeks) were studied on day 3 of life. Patients with suspected septicemia were randomized on day 1 of life in two groups. One group (n = 13) was administered 25 mg of ceftazidime per kg of body weight once daily, and the other (n = 15) was given 25 mg of ceftazidime per kg twice daily. Both groups also received 25 mg of amoxicillin per kg twice daily. Blood samples were collected on day 3 of life with an arterial catheter at 0, 0.5, 1, 2, 4, 8, and 12 h after an intravenous bolus injection. An additional blood sample was taken at 24 h from the group dosed once a day. High-performance liquid chromatography was used to determine serum ceftazidime concentrations. The pharmacokinetics of ceftazidime were best described by using a one-compartment model. The half-life for the elimination of the drug from serum, apparent volume of distribution, total body clearance of ceftazidime, and inulin clearance were not significantly different for both groups. The ceftazidime/inulin clearance ratio was 0.72 for both groups. However, trough concentrations in serum for the twice-daily group were significantly (P < 0.001) higher (42.0 +/- 13.4 mg/liter) than those for the once-daily group (13.1 +/- 4.7 mg/liter). The latter concentrations were all still substantially higher than the MIC of ceftazidime for major neonatal pathogens. We conclude that the currently recommended dosage of 25 mg of ceftazidime per kg twice daily for preterm infants with gestational ages below 32 weeks may be adjusted during the first days of life to one daily dose at 25 mg/kg, provided that for the empirical treatment of septicemia, amoxicillin at 25 mg/kg is also given twice daily.

Full Text

The Full Text of this article is available as a PDF (175.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balant L., Dayer P., Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet. 1985 Mar-Apr;10(2):101–143. doi: 10.2165/00003088-198510020-00001. [DOI] [PubMed] [Google Scholar]
  2. Boccazzi A., Rizzo M., Caccamo M. L., Assael B. M. Comparison of the concentrations of ceftazidime in the serum of newborn infants after intravenous and intramuscular administration. Antimicrob Agents Chemother. 1983 Dec;24(6):955–956. doi: 10.1128/aac.24.6.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Craig W. A., Ebert S. C. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother. 1992 Dec;36(12):2577–2583. doi: 10.1128/aac.36.12.2577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dubowitz L. M., Dubowitz V., Goldberg C. Clinical assessment of gestational age in the newborn infant. J Pediatr. 1970 Jul;77(1):1–10. doi: 10.1016/s0022-3476(70)80038-5. [DOI] [PubMed] [Google Scholar]
  6. Gentry L. O. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime. Pharmacotherapy. 1985 Sep-Oct;5(5):254–267. doi: 10.1002/j.1875-9114.1985.tb03424.x. [DOI] [PubMed] [Google Scholar]
  7. Gilman J. T. Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications. Clin Pharmacokinet. 1990 Jul;19(1):1–10. doi: 10.2165/00003088-199019010-00001. [DOI] [PubMed] [Google Scholar]
  8. Low D. C., Bissenden J. G., Wise R. Ceftazidime in neonatal infections. Arch Dis Child. 1985 Apr;60(4):360–364. doi: 10.1136/adc.60.4.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. McCracken G. H., Jr, Threlkeld N., Thomas M. L. Pharmacokinetics of ceftazidime in newborn infants. Antimicrob Agents Chemother. 1984 Oct;26(4):583–584. doi: 10.1128/aac.26.4.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mulhall A., de Louvois J. The pharmacokinetics and safety of ceftazidime in the neonate. J Antimicrob Chemother. 1985 Jan;15(1):97–103. doi: 10.1093/jac/15.1.97. [DOI] [PubMed] [Google Scholar]
  11. Neftel K. A., Hauser S. P., Müller M. R. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis. 1985 Jul;152(1):90–98. doi: 10.1093/infdis/152.1.90. [DOI] [PubMed] [Google Scholar]
  12. Paap C. M., Nahata M. C. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet. 1990 Oct;19(4):280–318. doi: 10.2165/00003088-199019040-00003. [DOI] [PubMed] [Google Scholar]
  13. Prinsloo J. G., Delport S. D., Moncrieff J., Paton A. M. A preliminary pharmacokinetic study of ceftazidime in premature, new born and small infants. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):361–364. doi: 10.1093/jac/12.suppl_a.361. [DOI] [PubMed] [Google Scholar]
  14. Prober C. G., Stevenson D. K., Benitz W. E. The use of antibiotics in neonates weighing less than 1200 grams. Pediatr Infect Dis J. 1990 Feb;9(2):111–121. doi: 10.1097/00006454-199002000-00009. [DOI] [PubMed] [Google Scholar]
  15. Schaad U. B., Guenin K., Steffen C., Herschkowtiz N. Effects of antimicrobial agents used for therapy of CNS infections on dissociated brain cell cultures. Pediatr Res. 1988 Sep;24(3):367–372. doi: 10.1203/00006450-198809000-00018. [DOI] [PubMed] [Google Scholar]
  16. Swabb E. A., Leitz M. A., Pilkiewicz F. G., Sugerman A. A. Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):131–140. doi: 10.1093/jac/8.suppl_e.131. [DOI] [PubMed] [Google Scholar]
  17. Verhagen C. A., Mattie H., Van Strijen E. The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br J Clin Pharmacol. 1994 Feb;37(2):193–197. doi: 10.1111/j.1365-2125.1994.tb04260.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W. A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988 Oct;158(4):831–847. doi: 10.1093/infdis/158.4.831. [DOI] [PubMed] [Google Scholar]
  19. de Louvois J., Dagan R., Tessin I. A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. European Society for Paediatric Infectious Diseases--Neonatal Sepsis Study Group. Eur J Pediatr. 1992 Dec;151(12):876–884. doi: 10.1007/BF01954122. [DOI] [PubMed] [Google Scholar]
  20. van den Anker J. N., Hop W. C., de Groot R., van der Heijden B. J., Broerse H. M., Lindemans J., Sauer P. J. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res. 1994 Nov;36(5):578–581. doi: 10.1203/00006450-199411000-00006. [DOI] [PubMed] [Google Scholar]
  21. van der Heijden A. J., Grose W. F., Ambagtsheer J. J., Provoost A. P., Wolff E. D., Sauer P. J. Glomerular filtration rate in the preterm infant: the relation to gestational and postnatal age. Eur J Pediatr. 1988 Oct;148(1):24–28. doi: 10.1007/BF00441807. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES